LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$21.86 USD
+1.21 (5.86%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $21.83 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for LENZ Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 186 | 268 | 377 | 20 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 7 | 5 | 1 | 0 |
Total Current Assets | 188 | 275 | 382 | 21 | 0 |
Net Property & Equipment | 0 | 23 | 7 | 1 | 0 |
Investments & Advances | 0 | 15 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 3 | 2 | 0 | 0 |
Total Assets | 188 | 322 | 402 | 23 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 3 | 2 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 6 | 4 | 2 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 29 | 0 |
Total Current Liabilities | 5 | 13 | 12 | 32 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 11 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 56 | 0 |
Total Liabilities | 5 | 26 | 18 | 88 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 551 | 540 | 525 | 5 | 0 |
Retained Earnings | -367 | -242 | -141 | -71 | -2 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 184 | 296 | 384 | -65 | -2 |
Total Liabilities & Shareholder's Equity | 188 | 322 | 402 | 23 | 0 |
Total Common Equity | 184 | 296 | 384 | -65 | -2 |
Shares Outstanding | 8.30 | 8.30 | 8.30 | NA | NA |
Book Value Per Share | 22.12 | 35.70 | 46.27 | 0.00 | 0.00 |
Fiscal Year End for LENZ Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 196 | 213 | 186 | 234 | 247 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 2 | 5 | 5 |
Total Current Assets | 199 | 217 | 188 | 239 | 251 |
Net Property & Equipment | 0 | 0 | 0 | 13 | 18 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 2 | 2 |
Total Assets | 203 | 217 | 188 | 266 | 287 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 7 | 0 | 4 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 12 | 4 | 5 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 19 | 5 | 13 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 10 | 19 | 5 | 62 | 63 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 315 | 310 | 551 | 548 | 546 |
Retained Earnings | -122 | -112 | -367 | -344 | -322 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 193 | 198 | 184 | 204 | 224 |
Total Liabilities & Shareholder's Equity | 203 | 217 | 188 | 266 | 287 |
Total Common Equity | 193 | 198 | 184 | 204 | 224 |
Shares Outstanding | 25.80 | 3.60 | 8.30 | 8.20 | 8.30 |
Book Value Per Share | 7.48 | 55.05 | 22.12 | 24.88 | 27.01 |